China Universal Asset Management Co. Ltd. Buys 1,367 Shares of Arvinas, Inc. (NASDAQ:ARVN)

China Universal Asset Management Co. Ltd. boosted its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 10.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,570 shares of the company’s stock after acquiring an additional 1,367 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Arvinas were worth $279,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. nVerses Capital LLC acquired a new stake in Arvinas in the 3rd quarter valued at approximately $39,000. KBC Group NV raised its position in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after purchasing an additional 440 shares during the period. Quantbot Technologies LP boosted its holdings in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares during the period. Finally, Exchange Traded Concepts LLC increased its stake in Arvinas by 37.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $164,000 after acquiring an additional 1,798 shares during the period. 95.19% of the stock is owned by institutional investors.

Arvinas Trading Down 1.6 %

Shares of ARVN stock opened at $17.61 on Monday. The stock has a 50-day moving average of $20.31 and a 200-day moving average of $23.89. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -3.77 and a beta of 1.87. Arvinas, Inc. has a 1-year low of $17.08 and a 1-year high of $53.08.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ARVN shares. Oppenheimer reduced their price target on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. BMO Capital Markets decreased their target price on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. Guggenheim reiterated a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. BTIG Research began coverage on Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective on the stock. Finally, Stephens assumed coverage on Arvinas in a research report on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price for the company. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $62.91.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.